Current Report Filing (8-k)
09 March 2017 - 11:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 9, 2017
Dimension Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
DELAWARE
|
|
001-37601
|
|
46-3942159
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
840 Memorial Drive, 4th Floor
Cambridge, MA
|
|
02139
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (617) 401-0011
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial Condition.
On March 9, 2017, Dimension Therapeutics, Inc. (the “Company”) issued a press release regarding its financial and operating results for the year
ended December 31, 2016. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report on Form 8-K.
The following
information and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release issued by the Company on March 9, 2017, furnished herewith.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: March 9, 2017
|
|
|
|
DIMENSION THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jean Franchi
|
|
|
|
|
|
|
|
Jean Franchi
|
|
|
|
|
|
|
|
Chief Financial Officer
|
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Jan 2025 to Feb 2025
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Dimension Therapeutics, Inc. (NASDAQ): 0 recent articles
More Dimension Therapeutics, Inc. News Articles
